GlaxoSmithKline to commercialise Cann Group cannabis medication
Medicinal cannabis producer Cann Group and global pharmaceutical firm GlaxoSmithKline are progressing negotiations relating to the commercialisation of Cann’s Satipharm CBD capsules. Cann Group, which operates a major cannabis growing and processing centre at Mildura, Victoria (pictured) announced it was in negotiation with GlaxoSmithKline’s Australian arm Haleon. The negotiations involve an exclusive agreement covering distribution…